TERAPIA COMBINADA CON ROSUVASTATINA Y EZETIMIBA (TREZETE) EN LA DISLIPIDEMIA DE MUY ALTO RIESGO CARDIOVASCULAR: EVIDENCIA DE EFICACIA E IMPACTO CLÍNICO
DOI:
https://doi.org/10.56238/levv16n54-030Palabras clave:
Dislipidemia, Rosuvastatina, Ezetimiba, Terapia Combinada, Riesgo CardiovascularResumen
La dislipidemia con muy alto riesgo cardiovascular requiere estrategias eficaces y seguras para la reducción intensiva del colesterol LDL. Esta revisión integrativa analizó estudios publicados entre 2015 y 2025 sobre la combinación de rosuvastatina/ezetimiba en pacientes con alto riesgo cardiovascular. La búsqueda se realizó en las bases de datos PubMed, Scopus, Web of Science, SciELO, LILACS y ScienceDirect. La combinación demostró una reducción adicional del colesterol LDL de hasta un 25 % en comparación con la monoterapia, con un perfil de seguridad favorable y mayor adherencia en las formulaciones de dosis fija. Se observaron resultados consistentes en subgrupos como diabéticos, ancianos y pacientes con enfermedad arterial coronaria (EAC). Las principales limitaciones incluyen el corto tiempo de seguimiento y la escasez de estudios comparativos con nuevas terapias hipolipemiantes. Se concluye que la combinación de rosuvastatina/ezetimiba es una alternativa eficaz, segura y aplicable en poblaciones de muy alto riesgo y debería considerarse como una opción de primera línea en escenarios de prevención cardiovascular intensiva.
Descargas
Referencias
AKYE, L. N.; KIRK, G. D.; KWON, S. Y. Rosuvastatin and Ezetimibe for Lipid Control in Dyslipidemia. American Journal of Preventive Cardiology, v. 10, n. 2, p. 81–88, 2025. DOI: https://doi.org/10.1016/j.ajpc.2025.07.015.
BAK, S. H. et al. Efficacy and safety of low-dose rosuvastatin/ezetimibe for dyslipidemia in patients with rheumatoid arthritis or osteoarthritis. Medicine, v. 104, n. 40, p. e33440, 2025. Disponível em: https://journals.lww.com/md-journal/fulltext/2025/07040/efficacy_and_safety_of_low_dose.101.aspx.
BRIE, D. M. et al. Dyslipidemia treatment in patients with acute coronary syndrome: is it time to move to combination therapy? Journal of Clinical Medicine, v. 14, n. 18, p. 6445, 2025. DOI: https://doi.org/10.3390/jcm14186445.
DODULÍK, J. et al. Triple non-statin therapy with ezetimibe, inclisiran, and bempedoic acid in patients with genetically confirmed statin-induced rhabdomyolysis: a dual case report. Pharmaceuticals, v. 18, n. 6, p. 818, 2025. DOI: https://doi.org/10.3390/ph18060818.
FERRI, N. Do anti-PCSK9 monoclonal antibodies have pleiotropic effects? JACC: Basic to Translational Science, v. 10, n. 5, p. 456–462, 2025. DOI: https://doi.org/10.1016/j.jacbts.2025.04.005.
FILINA, Z. V.; LITYUSHKINA, M. I.; ALAYEVA, Z. G. Analysis of methods for normalizing lipid profile and blood pressure in patients with chronic coronary syndromes. Medicine and Biotechnology, v. 15, n. 2, p. 78–84, 2025.
HUMMADI, A. et al. Whole exome sequencing identifies concurrent LDLR and ABCG8 mutations in a Saudi family with familial hypercholesterolemia and sitosterolemia. Frontiers in Genetics, v. 16, p. 1679594, 2025. DOI: https://doi.org/10.3389/fgene.2025.1679594.
KIM, H. L. et al. Real-world effectiveness of rosuvastatin–ezetimibe single pill (Rovazet®) in Korean dyslipidemia patients. Journal of Clinical Medicine, v. 14, n. 15, p. 5480, 2025. DOI: https://doi.org/10.3390/jcm14155480.
LIU, Y. et al. Comparative lipid-lowering effects of statin monotherapy versus statin plus ezetimibe: a meta-analysis. Journal of Clinical Lipidology, v. 15, n. 1, p. 45–52, 2023.
MATHIOUDAKIS, K. et al. Prevalence, incidence, and patterns of lipid-lowering treatment in Greece based on real-world nationwide data on 8,535,780 adults. Hellenic Journal of Cardiology, v. 66, n. 3, p. 213–221, 2025. DOI: https://doi.org/10.1016/j.hjc.2025.04.003.
PRIANI, S. E. et al. Formulation strategies for ezetimibe and its combinations: advancing biopharmaceutical and therapeutic potential. Drug Design, Development and Therapy, v. 19, p. 1357–1369, 2025. DOI: https://doi.org/10.2147/DDDT.S550340.
PARK, S. et al. Efficacy and safety of quadruple-drug fixed-dose single-pill combination therapy for hypertension and dyslipidemia: a prospective, multicenter study. Clinical Therapeutics, v. 47, n. 7, p. 1054–1065, 2025.
PERREGAUX, J. F.; GALLO, A. From histiocytosis to sitosterolemia: a case report. Atherosclerosis, v. 371, p. 122–125, 2025.
VARGHESE, A.; HEGELE, R. A. SAT-248 A case series of heterozygous familial hypercholesterolemia with PCSK9 inhibitor failure. Journal of the Endocrine Society, v. 9, suplemento 1, p. bvaf149.803, 2025.
WEI, H. et al. Effectiveness of fixed-dose rosuvastatin and ezetimibe in managing high cardiovascular risk dyslipidemia patients: a real-world observational study. Current Medical Research and Opinion, v. 39, n. 8, p. 1234–1242, 2024.
